Oncolytics Biotech Inc. (ONCY)

The U.S. Patent and Trademark Office granted a new patent covering key aspects of its proprietary manufacturing process for its investigational cancer immunotherapy Pelareorep.

Oncolytics Biotech said preclinical data showed its experimental immunotherapy produced stronger anti-tumor effects in combination therapy, supporting future studies in pancreatic and colorectal cancers.

Oncolytics Biotech (ONCY) is back on investors’ radars after early preclinical results showed its immunotherapy pelareorep combined with RAS inhibitors produced stronger anti tumor activity than either treatment alone in a solid tumor model. See our latest analysis for Oncolytics Biotech.

BiotechNewsPenny StocksHealth ... Investor Stockswhy it's moving ... A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes. ... Oncolytics Biotech, ...

P/E Ratio (0.000) is within average values for comparable stocks, (36.568). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.680). ONCY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (0.000) is also within normal v…